EUVIMEDEUVIMED entdecken
Multizentrische Studie

Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma

Chenglin Xie, Xu Ye, Li Zeng, Xi Zeng, Deliang Cao

Journal of Gastroenterology · 2023-10 · 58 (10) · 1030-1042

DOI: 10.1007/s00535-023-02011-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, 2023-10. Verfasst von Chenglin Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tongzipo Road, Changsha, 410013…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Special Projects of Changzhutan National Independent Innovation Demonstration Zone, Changsha Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: A large-scale multicenter study validated aldo-keto reductase 1B10 (AKR1B10) as a new serum marker of hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic value of serum AKR1B10 in HCC. METHODS: 273 naïve HCC patients enrolled for serum AKR1B10 tests were followed up for 2 years. Survival and clinical data were collected. Kaplan-Meier survival analysis and log-rank tests were used to estimate correlation of patient survival with serum AKR1B10. Univariate and multivariate COX regression analyses were used to evaluate the prognostic value of serum AKR1B10 level independently or in combination with other clinicopathological factors. α-fetoprotein (AFP) was analyzed in parallel for comparison. RESULTS: Serum AKR1B10 associated with tumor stage (p = 0.012), size (p = 0.004), primary tumor number (p = 0.019), and Child-Pugh classification (p = 0.003). HCC patients with a high level of serum AKR1B10 (≥ 267.9 pg/ml) had median survival (MS) of 25 months (95% confidence interval [CI] 20.788-29.212) vs. MS of 34 months (CI 28.911-39.089) in patients with normal serum AKR1B10 (p < 0.001). Univariate and multivariate COX regression analyses showed that serum AKR1B10 level was an unfavorable prognostic marker of HCC independently (HR 1.830, 95% CI 1.312-2.552; p < 0.001) or in combination with other clinical factors (HR 1.883, 95% CI 1.264-2.806; p = 0.002), such as TNM stage, tumor size and portal invasion. In the same cohort of HCC patients, AFP exhibited prognostic value at a cut-off of 400 ng/ml, but not at 20 ng/ml and 200 ng/ml. CONCLUSIONS: Serum AKR1B10 is a new prognostic marker of HCC, better than AFP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansAldo-Keto Reductasesalpha-FetoproteinsAldehyde ReductaseBiomarkers, TumorPrognosis

Stichwörter der Autor:innen

AFPAldo–keto reductase 1B10Hepatocellular carcinomaPrognostic markerSerum AKR1B10

Substanzen

Aldo-Keto Reductasesalpha-FetoproteinsAldehyde ReductaseBiomarkers, TumorAKR1B10 protein, human

Autor:innen und Institutionen

  • Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tongzipo Road, Changsha, 410013, Hunan, China.
  • The Affiliated Hospital of Hunan Research Institute of Traditional Chinese Medicine, 58 Lushan Road, Changsha, 410006, Hunan, China.
  • Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, 28W Changsheng Road, Hengyang, 421001, Hunan, China. xzeng@usc.edu…
  • Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tongzipo Road, Changsha, 410013, Hunan, China. dcao@usc.edu.cn.
  • Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, 28W Changsheng Road, Hengyang, 421001, Hunan, China. dcao@usc.edu.…

Förderung

  • Special Projects of Changzhutan National Independent Innovation Demonstration Zone
  • Changsha Municipal Natural Science Foundation

Zitieren

APA

Xie, C., Ye, X., Zeng, L., Zeng, X., & Cao, D. (2023). Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-023-02011-9

Vancouver

Xie C, Ye X, Zeng L, Zeng X, Cao D. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma. Journal of Gastroenterology. 2023. doi:10.1007/s00535-023-02011-9

BibTeX
@article{Xie2023,
  author = {Xie, Chenglin and Ye, Xu and Zeng, Li and Zeng, Xi and Cao, Deliang},
  title = {Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma},
  journal = {Journal of Gastroenterology},
  year = {2023},
  doi = {10.1007/s00535-023-02011-9}
}
Kostenlos starten →